Subscribe To

Price Alert Latest News Economic Calendar News

OMER / Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised by the FDA. Read More

Demo Live Account See Partner Details

Content Topics

Alpha

Architect

Merlyn

Ai

Tactical

Growth

And

Income

Etf

Snug

Omeros

Submits

Response

Regarding

Narsoplimab

Application

Hsct tma

Stock

OMER

Posted: Jan 20 2022, 06:54

Author Name: Benzinga

OMER News

By Reuters
October 16, 2023

Omeros to terminate kidney disease trial as therapy fails late-stage study

Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of

By Seeking Alpha
July 21, 2023

Omeros Corporation - Still Looking Too Risky For A Buy Rating

Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's l

By Business Wire
June 21, 2023

Omeros Announces Webcast Details for Annual Meeting of Shareholders

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareh

By The Motley Fool
June 12, 2023

Why Shares of Omeros Dropped on Monday

The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash.

By Seeking Alpha
May 9, 2023

Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript

Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations G

By Seeking Alpha
March 13, 2023

Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript

Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relatio

By The Motley Fool
February 9, 2023

Why Omeros Stock Bolted Higher This Week

A $200 million milestone payment sparked a rally in the biopharma's shares this week.

By Seeking Alpha
February 8, 2023

Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy

Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang som

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.